Key facts
- Sai Parenteral's (NSE: SAIPARENT)’s last known valuation is $185.9M (Apr 2026).
- It has raised $40.3M; the latest was IPO ($43.9M) in Apr 2026.
- Notable investors include Kailas Family Trust, AIG Direct Insurance Services, Arihant Capital Markets, Blue Lotus Capital, Magnifiq Capital Trust — 8 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sai Parenteral's (NSE: SAIPARENT)
- ·The full record, as it builds
Funding rounds
No funding rounds for Sai Parenteral's (NSE: SAIPARENT) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sai Parenteral's (NSE: SAIPARENT)
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
- Sector
- Healthcare
- HQ
- Hyderabad, India
- Founded
- 2001
- Employees
- 298
- Website
- saiparenterals.com/
- Ownership
- Publicly Held
Sai Parenteral's (NSE: SAIPARENT) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sai Parenteral's (NSE: SAIPARENT) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sai Parenteral's (NSE: SAIPARENT) in its N-PORT filings yet. We sweep new filings monthly.